- Home
- JMM vs ALXO Comparison
JMM vs ALXO Comparison
Compare JMM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMM | ALXO |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 68.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JMM | ALXO |
|---|---|---|
| Price | $6.01 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 16.1K | ★ 189.6K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.29 | $0.40 |
| 52 Week High | $6.10 | $2.27 |
Technical Indicators
Market Signals| Indicator | JMM | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 52.99 |
| Support Level | $5.89 | $1.07 |
| Resistance Level | $6.06 | $1.18 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 88.24 | 63.04 |
Price Performance
Historical ComparisonAbout JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.